Schwangerschaft bei chronisch-entzündlichen Darmerkrankungen

ZUSAMMENFASSUNG

Die höchsten gemeldeten Prävalenzraten für die chronisch-entzündlichen Darmerkrankungen (CED) Morbus Crohn und Colitis ulcerosa liegen aktuell in Europa. Etwa die Hälfte der Patienten sind Frauen und die meisten davon sind im reproduktionsfähigen Alter. Die Betreuung von schwangeren Patientinnen mit CED ist eine Herausforderung für interdisziplinäre Behandlungsteams. Die Auswirkungen der CED und ihrer Therapien auf Schwangerschaft, Neugeborene und Stillzeit sowie die Auswirkungen einer Schwangerschaft auf die CED und die Gesundheit der Mütter werden häufig mit Angst und Sorge betrachtet. Oft wird die Therapie bei Schwangerschaft und Stillzeit abgebrochen, ein signifikantes Risiko für eine Verschlechterung der Krankheitsaktivität und somit das größte bekannte Risiko für Schwangerschaft und Geburt. Frauen und Schwangere mit CED optimal zu betreuen erfordert eine interdisziplinäre Zusammenarbeit bei Diagnostik, Therapie und Prävention.

• Literatur

• 1 Barmer GEK: https://www.barmer.de/blob/71456/1f5b78999d9b260f1b2a6ccbc4518170/data/die-chronisch-entzuendlichen-darmerkrankungen-morbus-crohn-und-colitis-ulcerosa.pdf abgerufen am 04.07.2019
• 2 Ng SC, Shi HY, Hamidi N. et al Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769-2778
• 3 Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Experiment Gastroenterol 2016; 9: 325-335
• 4 Cornish J, Tan E, Teare J. et al A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-837
• 5 Molnar T, Farkas K, Nagy F. et al Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol 2010; 45: 1302-1306
• 6 Nguyen GC, Seow CH, Maxwell C. et al The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016; 150: 734-57 e1
• 7 Preiß JC, Bokemeyer B, Buhr HJ. et al Aktualisierte S3-Leitlinie – Morbus Crohn. Z Gastroenterol 2014; 52: 1431-1484
• 8 Ng SC, Shi HY, Hamidi N. et al Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769-2778
• 9 Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Experiment Gastroenterol 2016; 9: 325-335
• 10 Cornish J, Tan E, Teare J. et al A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-837
• 11 Centers for Disease Control and Prevention. U. S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 1-88
• 12 Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease. Ann Gastroenterol 2018; 31: 14-23
• 13 Moller FT, Andersen V, Wohlfahrt J. et al Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol 2015; 110: 564-571
• 14 Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991; 100: 1638-1643
• 15 Laharie D, Debeugny S, Peeters M. et al Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120: 816-819
• 16 Cornish JA, Tan E, Teare J. et al The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 2007; 50: 1128-1138
• 17 Rajaratnam SG, Eglington TW, Hider P. et al Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Colorectal Dis 2011; 26: 1365-1374
• 18 Livingston D, Cohn D. Childlessness Up Among All Women. Down Among Women with Advanced Degrees.. Pew Research Center; Washington, DC: 2010
• 19 Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 2017; 152: 451-462 e2
• 20 Friedman S, Larsen PV, Fedder J. et al The reduced chance of a live birth in women with IBD receiving assisted reproduction is due to a failure to achieve a clinical pregnancy. Gut 2017; 66: 556-558
• 21 Leung YP, Kaplan GG, Coward S. et al Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease. J Crohns Colitis 2015; 9: 223-230
• 22 Seow CH, Leung Y, Vande Casteele N. et al The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 1329-1338
• 23 Mahadevan U, Dubinsky MC, Su C. et al Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflamm Bowel Dis 2018; 24: 2494-2500
• 24 Mullin GE. Micronutrients and inflammatory bowel disease. Nutr Clin Pract 2012; 27: 136-137
• 25 Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 460-466
• 26 Norgard B, Hundborg HH, Jacobsen BA. et al Disease activity in pregnant women with Crohn’s disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102: 1947-1954
• 27 Hatch Q, Champagne BJ, Maykel JA. et al Crohn’s disease and pregnancy: the impact of perianal disease on delivery methods and complications. Dis Colon Rectum 2014; 57: 174-178
• 28 Chaparro M, Verreth A, Lobaton T. et al Long-term safety of in utero exposure to anti-tnfα drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study. Am J Gastroenterol 2018; 113: 396-403
• 29 Dignass A, Van Assche G, Lindsay JO. et al The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28-62
• 30 Norgard B, Pedersen L, Christensen LA. et al Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413
• 31 Bandoli G, Palmsten K, Forbess Smith CJ. et al A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am 2017; 43: 489-502
• 32 Luu M, Benzenine E, Doret M. et al Continuous anti-Tnfα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol 2018; 113: 1669-1677
• 33 Remzi FH, Gorgun E, Bast J. et al Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum 2005; 48: 1691-1699
• 34 Nguyen GC, Bernstein CN, Bitton A. et al Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146: 835-848 e6
• 35 Bates SM, Middeldorp S, Rodger M. et al Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41: 92-128